Next generation sequencing detection of late onset pompe disease

Corrado Angelini, Marco Savarese, Marina Fanin, Vincenzo Nigro

Research output: Contribution to journalArticlepeer-review


Introduction: We report a patient in whom the diagnosis of a treatable disease was delayed for 30 years. Methods: Recent discoveries of next generation sequencing (NGS) have allowed us to reconsider the diagnosis of limb girdle muscular dystrophy (LGMD) cases of unknown etiology. Results: A 36-year-old man appeared to have LGMD with onset in shoulder girdle muscles, but all sarcolemmal and cytoskeletal proteins tested by immunoblotting and immunohistochemistry gave normal results. He developed respiratory insufficiency and became dependent on overnight ventilation at age 44. By NGS technology, 2 mutations in the GAA gene (intervening sequence 1 and a missense mutation in exon 11) allowed us to make a definite diagnosis of glycogenosis type II (Pompe disease) and start enzyme replacement therapy at age 71. Conclusions: Mild nondystrophic features on muscle biopsy and respiratory muscle involvement should suggest late-onset Pompe disease in patients with an unclassified LGMD phenotype. NGS may help make the diagnosis.

Original languageEnglish
Pages (from-to)981-983
Number of pages3
JournalMuscle and Nerve
Issue number6
Publication statusPublished - Jun 1 2016


  • Acid maltase
  • ERT
  • GAA
  • Late onset Pompe disease
  • NGS

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology


Dive into the research topics of 'Next generation sequencing detection of late onset pompe disease'. Together they form a unique fingerprint.

Cite this